Previous Close | 61.56 |
Open | 61.56 |
Bid | 47.25 |
Ask | 52.35 |
Strike | 190.00 |
Expire Date | 2024-07-19 |
Day's Range | 61.56 - 61.56 |
Contract Range | N/A |
Volume | |
Open Interest | N/A |
The FDA approved Moderna's RSV vaccine, allowing the biotech to launch its second-ever product. But Moderna stock retreated.
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes CAMBRIDGE, MA / ACCESSWIRE / May 31, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) ...
Moderna stock is on the rise again as investors focus on the potential need for a bird flu vaccine. Is MRNA stock a buy right now?